Eli Lilly has agreed to acquire Kelonia Therapeutics in a deal worth up to $7 billion, aiming to strengthen its oncology pipeline with next generation in vivo CAR-T cell therapies.
Glimpse:
Announced in April 2026, Eli Lilly will acquire Kelonia Therapeutics for up to $7 billion, including $3.25 billion upfront and additional milestone based payments. The deal focuses on Kelonia’s in vivo CAR-T platform, which enables cancer treatment by engineering immune cells directly inside the patient’s body.
Eli Lilly has entered into a definitive agreement to acquire Boston based biotech firm Kelonia Therapeutics, marking a major expansion of its oncology and genetic medicine capabilities.
The deal is valued at up to $7 billion, with $3.25 billion paid upfront and the remaining amount tied to clinical, regulatory, and commercial milestones.
Kelonia specializes in in vivo CAR-T cell therapy, an emerging approach that enables the body to generate its own cancer fighting immune cells internally. This represents a major shift from traditional CAR-T therapies, which require extracting and modifying cells outside the body before reinfusion.
The company’s lead candidate, KLN-1010, is currently in early stage clinical trials targeting multiple myeloma, a type of blood cancer. Early findings suggest the therapy could simplify treatment while maintaining effectiveness, potentially improving patient access and reducing costs.
For Eli Lilly, the acquisition aligns with its broader strategy to expand beyond its dominant diabetes and obesity portfolio and build a stronger presence in oncology a rapidly growing global market.
Industry experts view in vivo CAR-T as a potential breakthrough in cancer treatment due to its scalability, reduced complexity, and ability to eliminate chemotherapy and complex manufacturing processes.
The transaction is expected to close in the second half of 2026, subject to regulatory approvals and customary conditions.
Overall, the acquisition highlights a growing trend in the pharmaceutical industry, where major players are investing heavily in next-generation cell and gene therapies to drive future growth and innovation in cancer care.
“In vivo CAR-T is viewed as the ‘holy grail’ of cell therapy.”
By
HB Team
Related News
